| abstract |
Disclosed are methods for modifying or regulating at least one of glucose or lipid metabolism disorders which comprises administering to a human or vertebrate subject a D 1 dopamine agonist in conjunction with a dopamine D 2 agonist where the conjoined administration is effective to improve at least one of the following lipid and glucose metabolic indices: body weight, body fat, plasma insulin, plasma glucose and plasma lipid, and plasma lipoprotein. In preferred embodiments, the administration of the D 1 dopamine agonist and the D 2 dopamine agonist is conducted at a predetermined time. |